14021-14-8
14021-14-8 structure
- Name: Randialic acid B
- Chemical Name: 3β-hydroxyurs-12,18-dien-28-oic acid
- CAS Number: 14021-14-8
- Molecular Formula: C30H46O3
- Molecular Weight: 454.68400
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2018-04-05 07:43:59
- Modify Date: 2024-01-12 21:29:44
-
Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks FPR1 in human neutrophils and attenuates psoriasis-like inflammation in vivo[1].
| Name | 3β-hydroxyurs-12,18-dien-28-oic acid |
|---|---|
| Synonyms |
randialic acid-B
3β-Hydroxy-ursadien-(12.18)-saeure-(28) 3β-hydroxy-ursadien-(12.18)-oic acid-(28) Vanguerolsaeure (2R,4aS,6aS,6bR,8aR,10S,12aR,12bR)-10-Hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13-hexadecahydro-2H-picene-4a-carboxylic acid |
| Description | Randialic acid B, a triterpenoid compound, is a formyl peptide receptor 1 (FPR1) antagonist. Randialic acid B blocks FPR1 in human neutrophils and attenuates psoriasis-like inflammation in vivo[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Randialic acid B (0.1-3 μM; for 5 min) selectively inhibits reactive oxygen species production, elastase release, and CD11b expression in human neutrophils activated by FPR1. Randialic acid B inhibits the binding of N-formyl peptide to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells, indicating FPR1 antagonism[1]. Randialic acid B acts competitively for its binding to the FPR1 receptor. The FPR1-downstream signaling such as Ca2+ mobilisation and activation of Akt and MAPKs is also competitively inhibited[1]. Randialic acid B shows significant cell-protective effects against H2O2-induced H9c2 cardiomyocyte injury[2]. |
| In Vivo | Randialic acid B (10 mg/kg; i.v.; every other day; for 5 days) significantly reduces Imiquimod-induced psoriasis-like symptom, including epidermal hyperplasia, desquamation with scaling, neutrophil skin infiltration, and transepidermal water loss[1]. Animal Model: BALB/c white female mice (20 g weight; 7-week-old) treated with Imiquimod[1] Dosage: 10 mg/kg Administration: i.v.; every other day; for 5 days Result: Significantly reduced Imiquimod-induced psoriasis-like symptoms. |
| References |
| Molecular Formula | C30H46O3 |
|---|---|
| Molecular Weight | 454.68400 |
| Exact Mass | 454.34500 |
| PSA | 57.53000 |
| LogP | 7.15370 |